Role of F-fluorodeoxyglucose Positron-emission Tomography/computed Tomography in Restaging of Adrenocortical Carcinoma

Overview

Journal Rep Pract Oncol Radiother

Specialty Oncology

Date 2024 Mar 22

PMID 38515818

Authors

Hakan Ozturk

Affiliations

Soon will be listed here.

Abstract

Background: The objective was to retrospectively evaluate the contribution of fluorodeoxyglucose [F] positron emission tomography/computed tomography (FDG-PET/CT) to the re-staging of adrenocortical carcinoma (ACC).

Materials And Methods: A total of 16 patients (10 males and 6 females), who underwent adrenalectomy due to adrenocortical carcinoma and FDG-PET/CT scan to re-stage the tumor between July 2007 and April 2013, were included in the present study. The mean age was 53.37 ± 13.91 years (min: 30, max: 74) The patients were required to fast for six hours prior to scanning, and whole-body PET scanning from the skull base to the upper thighs was performed approximately 1 h after the intravenous injection of 555 MBq of F-18 FDG. Whole body CT scanning was performed in the cranio-caudal direction. FDG-PET images were reconstructed using CT data for attenuation correction. Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up.

Results: Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of FDG-PET/CT were 100%, 83.3%, 90.9%, 83.3%, and 93.7%, respectively.

Conclusion: FDG-PET/CT detects local recurrence and/or distant metastases with high accuracy in the re-staging of operated adrenocortical carcinoma. It is considered that the procedure could play an important role in treatment decision after the operation and post-operative follow-up and could influence the entire decision-making process.

References

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Boland G, Dwamena B, Jagtiani Sangwaiya M, Goehler A, Blake M, Hahn P . Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology. 2011; 259(1):117-26. DOI: 10.1148/radiol.11100569. View

Bilimoria K, Shen W, Elaraj D, Bentrem D, Winchester D, Kebebew E . Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113(11):3130-6. DOI: 10.1002/cncr.23886. View

Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller S, Beyer T . Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol. 2004; 22(21):4357-68. DOI: 10.1200/JCO.2004.08.120. View

Cegla P, Bryl M, Witkowska K, Bos-Liedke A, Pietrasz K, Kycler W . Differences between TNM classification and 2-[F]FDG PET parameters of primary tumor in NSCLC patients. Rep Pract Oncol Radiother. 2021; 26(3):445-450. PMC: 8281901. DOI: 10.5603/RPOR.a2021.0072. View

Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y . Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001; 25(7):891-7. DOI: 10.1007/s00268-001-0047-y. View

Wahl R, Jacene H, Kasamon Y, Lodge M . From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1:122S-50S. PMC: 2755245. DOI: 10.2967/jnumed.108.057307. View

Meier J, Alavi A, Iruvuri S, Alzeair S, Parker R, Houseni M . Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med. 2007; 37(3):154-72. DOI: 10.1053/j.semnuclmed.2007.02.001. View

Bagheri B, Maurer A, Cone L, Doss M, Adler L . Characterization of the normal adrenal gland with 18F-FDG PET/CT. J Nucl Med. 2004; 45(8):1340-3. View

10.

Leboulleux S, Dromain C, Bonniaud G, Auperin A, Caillou B, Lumbroso J . Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2005; 91(3):920-5. DOI: 10.1210/jc.2005-1540. View

11.

Becherer A, Vierhapper H, Potzi C, Karanikas G, Kurtaran A, Schmaljohann J . FDG-PET in adrenocortical carcinoma. Cancer Biother Radiopharm. 2001; 16(4):289-95. DOI: 10.1089/108497801753131363. View

12.

Senthil R, Mittal B, Kashyap R, Bhattacharya A, Radotra B, Bhansali A . ¹⁸F FDG PET/CT demonstration of IVC and right atrial involvement in adrenocortical carcinoma. Jpn J Radiol. 2011; 30(3):281-3. DOI: 10.1007/s11604-011-0037-4. View

13.

Chuang H, Deniz F, Sircar K, Jimenez C, de Celis C, Wood C . [¹⁸F]Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case. J Clin Oncol. 2012; 30(26):e246-9. PMC: 3434990. DOI: 10.1200/JCO.2011.40.6710. View

14.

Lee D, Kim S, Lee H, Lee S, Park S, Kim H . Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer. J Thorac Oncol. 2009; 4(7):816-21. DOI: 10.1097/JTO.0b013e3181a99fde. View

15.

Gross M, Avram A, Fig L, Fanti S, Al-Nahhas A, Rubello D . PET in the diagnostic evaluation of adrenal tumors. Q J Nucl Med Mol Imaging. 2007; 51(3):272-83. View

16.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

17.

Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P . Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006; 91(7):2650-5. DOI: 10.1210/jc.2005-2730. View

18.

Mackie G, Shulkin B, Ribeiro R, Worden F, Gauger P, Mody R . Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006; 91(7):2665-71. DOI: 10.1210/jc.2005-2612. View

19.

Timmers H, Kozupa A, Chen C, Carrasquillo J, Ling A, Eisenhofer G . Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007; 25(16):2262-9. DOI: 10.1200/JCO.2006.09.6297. View

20.

Hennings J, Lindhe O, Bergstrom M, Langstrom B, Sundin A, Hellman P . [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab. 2006; 91(4):1410-4. DOI: 10.1210/jc.2005-2273. View